# XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT05005728** · PHASE2 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **COMBINATION_PRODUCT:** vudalimab + carboplatin + cabazitaxel
- **COMBINATION_PRODUCT:** vudalimab + olaparib
- **BIOLOGICAL:** vudalimab monotherapy
- **COMBINATION_PRODUCT:** vudalimab + docetaxel
- **COMBINATION_PRODUCT:** vudalimab + cabazitaxel or docetaxel

## Key facts

- **NCT ID:** NCT05005728
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-22
- **Primary completion:** 2025-06-10
- **Final completion:** 2025-06-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005728, "XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05005728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*